Good for Business, Health, Industry, Latvia, Markets and Companies, Medicine
International Internet Magazine. Baltic States news & analytics
Saturday, 20.04.2024, 09:29
Non-audited profit for Grindeks EUR 12.9 mln in 2019
The Group’s turnover in 2019 was EUR 141.4 mln. In 2019, the
Group’s production was exported to 84 countries worldwide, a total of EUR 132 mln.
''The last year was a success as we managed to reach 12.9 mln
euro in profit – this is a guarantee for the further development of the Group.
In the recent years, the pharmaceutical industry has been changing, and now
pharmaceutical businesses must operate in an environment where customer needs
are becoming more specific. Grindeks Group potential to offer solutions
tailored to customer needs is very high. Our strategic business development
goal is to be one step forward of the intense competition and expand Grindeks
activities in our traditional markets, and in European Union, South East Asia
countries and the USA,'' the company's board chairman Juris Hmelnickis said.
Sales volume of the final dosage forms in 2019 was EUR 132.2
mln. In 2019, the sales amount in Russia, the other CIS countries and Georgia
reached EUR 77.9 mln. In comparison to 2018, in 2019 the biggest increase in
sales volume was reached in Belarus (20 %), Georgia (18 %), Moldova (13 %) and
Armenia (12 %).
Sales volume of the final dosage forms in the EU countries
in 2019 reached EUR 50.2 mln. Sales volume in 2019, compared with 2018,
increased by 3 times in France, by 2 times in Sweden and Czech Republic, by 52 %
in Hungary and by 46 % in Great Britain.
In 2019, sales of the active pharmaceutical ingredients
reached EUR 8.6 mln. During this reporting period Grindeks mostly exported its
active pharmaceutical ingredients to the EU countries, Japan, Australia and
Canada. The most required active pharmaceutical ingredients of Grindeks in 2019
were dexmedetomidine, xylazine and pimobendan.
In 2018, Grindeks operated with EUR 145.477 mln in turnover,
and posted EUR 9.737 mln in losses.
In 2019, products of the company were exported to 84
countries. The most significant Grindeks markets include the EU countries,
Russia and the other CIS countries, the USA, Canada and Japan.
- 28.01.2022 BONO aims at a billion!
- 13.02.2021 Моя жизнь в газете. Очерки по новейшей истории Латвии. Глава 1
- 25.01.2021 Как банкиры 90-х делили «золотую милю» в Юрмале
- 30.12.2020 Накануне 25-летия Балтийский курс/The Baltic Course уходит с рынка деловых СМИ
- 30.12.2020 On the verge of its 25th anniversary, The Baltic Course leaves business media market
- 30.12.2020 Business Education Plus предлагает анонсы бизнес-обучений в январе-феврале 2021 года
- 30.12.2020 Hotels showing strong interest in providing self-isolation service
- 30.12.2020 EU to buy additional 100 mln doses of coronavirus vaccine
- 30.12.2020 ЕС закупит 100 млн. дополнительных доз вакцины Biontech и Pfizer
- 29.12.2020 В Rietumu и в этот раз создали особые праздничные открытки и календари 2021